Alzinova AB is a Swedish biotechnology enterprise engaged in drug discovery research for Alzheimer’s disease. The company's proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.Read more »
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy. The unique properties of the AβCC peptide™ technology has also enabled the development of a monoclonal antibody with 100% specificity for the synapse-damaging oligomers. It is currently under validation as a diagnostic tool.
Alzheimer’s Disease International’s recently published World Alzheimer Report 2015 provides fresh statistics on the global impact… Read more »
Alzinova has received a notice of allowance for the AβCC Peptide Technology patent application in Japan.… Read more »
Alzinova is seeking a CEO to build and lead the organization into a new chapter of growth (in Swedish)
Alzinova söker affärsinriktad VD med erfarenhet inom bioteknik Vi söker omgående en affärsinriktad och entreprenöriell… Read more »